Penumbra Inc. logo

Penumbra Inc.

PEN | NYSE
Chart Builder DCF Calculator
$319.35
+$0.40 (+0.13%)
Nov 2, 2026, 9:32 AM ET · Market open
+0.13%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026
57.3
+1.5 pts
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #153/1028 (Top 15%)

Key Statistics

Market Data

Market Cap $12.59B
1D Range
318.59 320.00
52W Range
225.54 359.40

Valuation (TTM)

PE 80.34
PB 7.93
EV/EBITDA 52.79

Valuation (NTM)

Forward PE 50.92
Forward PEG 3.13
Price Target $320.00
Loading financial charts...

Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; ...

Sector Healthcare
Employees 4,700
IPO Date Sep 18, 2015
Fiscal Year January - December

Latest News

Penumbra, Inc. Reports Third Quarter 2026 Financial Results

3 days ago · prnewswire.com

Penumbra, Inc. Reports Third Quarter 2026 Financial Results
Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

13 days ago · prnewswire.com

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

27 days ago · prnewswire.com

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
Reasons to Retain Penumbra Stock in Your Portfolio for Now

2 months ago · zacks.com

Reasons to Retain Penumbra Stock in Your Portfolio for Now
Penumbra, Inc. Reports Second Quarter 2026 Financial Results

3 months ago · prnewswire.com

Penumbra, Inc. Reports Second Quarter 2026 Financial Results
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

3 months ago · gurufocus.com

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke

4 months ago · prnewswire.com

First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?

5 months ago · zacks.com

Penumbra Receives CE Nod for THUNDERBOLT: Stock to Gain?
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT

5 months ago · prnewswire.com

Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

5 months ago · prnewswire.com

Penumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke

Earnings

Latest Earnings
Oct 29, 2026
EPS
$1.07
Miss -10.83%
REV
$410.15M
Beat +2.18%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
14
Consensus
Hold
Price Target
$320.00
Upside
+0.20%
Buy (3)
Hold (10)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.